Lipoproteins are the body’s lipid transport vehicles: tiny spherical particles that shuttle cholesterol and fats through the bloodstream, which is mostly water and therefore hostile to oily molecules traveling alone. Each lipoprotein has a fatty core wrapped in a water-friendly shell, and the different types (chylomicrons, VLDL, LDL, HDL, and the less-discussed Lp(a)) serve distinct roles in moving fat from the gut, the liver, or peripheral tissues to wherever it is needed or stored. Understanding how these particles are built, where they travel, and what goes wrong when the system falls out of balance is central to understanding heart disease, metabolic disorders, and even brain health.
How a Lipoprotein Is Built
Think of a lipoprotein as a tiny oil droplet designed to survive in water. The interior core holds the water-insoluble cargo: cholesterol esters and triglycerides. Surrounding that core is a single-layer shell made of phospholipids and free cholesterol, with their water-friendly heads facing outward and their oily tails facing inward toward the core. Proteins called apolipoproteins sit embedded in or draped across this outer shell, serving as both structural scaffolding and molecular ID badges that tell the body’s cells what to do with the particle.1IntechOpen. Structure of Lipoproteins and Their Capacity for Lipid Exchange: Relevance for Development of Atherosclerosis and Its Treatment by HDL Therapy
This core-shell architecture is remarkably consistent across all lipoprotein classes. Early compositional analysis of human plasma lipoproteins showed that whether the particle is enormous (like a chylomicron) or small (like HDL), they all follow the same spherical blueprint: a liquid lipid core whose radius is about 20 angstroms smaller than the overall particle, coated by a phospholipid-cholesterol monolayer with proteins packed tightly at the surface.2PubMed Central. Structure of human serum lipoproteins inferred from compositional analysis What varies between lipoprotein classes is the ratio of triglycerides to cholesterol in the core, the overall particle size, and which apolipoproteins ride along on the surface. Those differences dictate where the particle comes from, where it goes, and how the body processes it.
The Major Lipoprotein Classes
You will see lipoproteins grouped by density, which is how they were originally separated in the lab using ultracentrifugation. Particles carrying more fat (especially triglycerides) are larger and less dense; particles carrying more protein relative to fat are smaller and denser. From lowest to highest density:
- Chylomicrons: The largest and least dense lipoproteins, assembled in the gut after you eat a fatty meal. Their job is to carry dietary triglycerides into the bloodstream.
- VLDL: Very low-density lipoproteins, made by the liver. These carry triglycerides synthesized internally rather than absorbed from food.
- LDL: Low-density lipoproteins, the particles left behind after VLDL has shed most of its triglycerides. LDL is cholesterol-rich and delivers cholesterol to cells throughout the body.
- HDL: High-density lipoproteins, the smallest and densest class. HDL picks up excess cholesterol from tissues and returns it to the liver for disposal.
Each class carries a characteristic set of apolipoproteins. Chylomicrons carry apoB-48; VLDL and LDL carry apoB-100; HDL carries apoA-I. These surface proteins are not just labels. They activate enzymes, bind to receptors on cell surfaces, and regulate how quickly the particle is cleared from circulation.
The Exogenous Pathway: Getting Dietary Fat Into the Body
When you eat something fatty, the fat gets broken down in the small intestine and absorbed by cells lining the gut wall (enterocytes). Inside these cells, the absorbed triglycerides need to be repackaged for transport. The enterocytes assemble chylomicrons using three key ingredients: apoB-48, a protein called microsomal triglyceride transfer protein (MTP), and apoA-IV.3PubMed. Development and physiological regulation of intestinal lipid absorption. I. Development of intestinal lipid absorption: cellular events in chylomicron assembly and secretion MTP is particularly critical. Animal studies have shown that without functioning MTP, triglyceride absorption essentially stops, and fat accumulates inside the gut cells with nowhere to go.4PubMed Central. Intestinal lipid absorption and lipoprotein formation
Once secreted into the lymphatic system and then the bloodstream, chylomicrons encounter an enzyme called lipoprotein lipase (LPL), which sits on the inner walls of blood vessels in muscle, fat tissue, and other organs. LPL breaks down the chylomicron’s triglyceride cargo into fatty acids that nearby cells can absorb for energy or storage. As the chylomicron loses its triglycerides, it shrinks into a smaller “remnant” particle that the liver recognizes and pulls out of circulation. The efficiency of this whole process depends on a delicate balance of activating and inhibiting signals: apoC-II activates LPL, while apoC-I and apoC-III can inhibit it by physically displacing the enzyme from the fat droplet surface.5PubMed Central. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets
The Endogenous Pathway: From Liver-Made VLDL to LDL
Your liver constantly produces its own triglyceride-rich particles, VLDL, regardless of what you recently ate. VLDL enters the bloodstream and undergoes the same LPL-mediated stripping of triglycerides that chylomicrons experience. As triglycerides are removed, VLDL shrinks and becomes denser, passing through an intermediate stage sometimes called VLDL remnants (or IDL, intermediate-density lipoproteins). About half of these remnants are recognized and cleared by the liver through several receptor types. The other half lose enough triglycerides and surface proteins to become LDL, the cholesterol-dense particle that delivers cholesterol to cells throughout the body.6PubMed Central. Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets
LDL is cleared from the blood primarily through a receptor on cell surfaces called the LDL receptor (LDLR). When a cell needs cholesterol, it puts more LDL receptors on its surface; when it has enough, it reduces them. LDL binds to its receptor, the whole complex gets pulled inside the cell through a process called receptor-mediated endocytosis, and the cholesterol is released internally for use in building cell membranes, making hormones, or other functions.7PubMed Central. Last step in the path of LDL cholesterol from lysosome to plasma membrane to ER is governed by phosphatidylserine
PCSK9 and the Fate of the LDL Receptor
A protein called PCSK9 plays a surprisingly powerful role in controlling how much LDL stays in your blood. Under normal conditions, after an LDL receptor pulls LDL into a cell, the receptor itself gets recycled back to the cell surface for another round of LDL pickup. PCSK9 interferes with that recycling. It binds to the LDL receptor and reroutes it for destruction rather than reuse, which means fewer receptors are available to clear LDL from the blood.8PubMed Central. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells Lab experiments have shown that overproducing PCSK9 does not reduce how many LDL receptors a cell makes, but it dramatically speeds up the rate at which existing receptors are degraded.9PubMed Central. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
This makes PCSK9 a major drug target. If you block PCSK9, more LDL receptors survive and keep clearing LDL from the bloodstream, lowering cholesterol. Several therapeutic approaches now exploit this: monoclonal antibodies like evolocumab and alirocumab bind to PCSK9 directly, while newer RNA-based therapies silence the gene that produces PCSK9 in the first place.10PubMed. Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective
Reverse Cholesterol Transport: HDL’s Cleanup Role
If the exogenous and endogenous pathways are about delivering lipids outward, reverse cholesterol transport (RCT) is the return trip. It is the process by which excess cholesterol in peripheral tissues gets shuttled back to the liver for excretion, and HDL is the workhorse behind it. The process starts when a transporter protein called ABCA1 on the surface of cells (especially macrophages in artery walls) pumps cholesterol and phospholipids out onto lipid-free apoA-I, the main protein component of HDL.11PubMed Central. The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids A second transporter, ABCG1, also moves cholesterol outward but hands it off to mature HDL particles rather than lipid-free apoA-I.12PubMed. Different Pathways of Cellular Cholesterol Efflux
Once cholesterol is loaded onto the nascent HDL particle, an enzyme called LCAT converts the free cholesterol into cholesterol esters, which are more hydrophobic and migrate into the particle’s core. This transformation converts small, disc-shaped early HDL into the larger, spherical mature HDL you see measured in standard blood tests.13Endocrinology and Metabolism. High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis The cholesterol cargo eventually reaches the liver via SR-B1, a receptor on liver cells that selectively extracts cholesterol esters from HDL without destroying the particle itself.14PubMed Central. SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux SR-B1 is most abundant in the liver, where the imported cholesterol feeds into bile acid production, and in steroid-producing glands, where the cholesterol is used as raw material for hormones.15PubMed Central. Scavenger receptor B type 1: expression, molecular regulation, and cholesterol transport function
Another protein, CETP, complicates the picture by exchanging cholesterol esters on HDL for triglycerides on VLDL and LDL. This reshuffles lipid content between particle classes and is one reason HDL cholesterol levels alone do not perfectly predict cardiovascular protection.
How Cellular Cholesterol Levels Stay in Check
Cells do not passively accept whatever cholesterol arrives. They have an internal monitoring system built around a protein complex involving SREBP, Scap, and Insig. When cholesterol levels inside the cell drop, Scap escorts SREBP to a processing site where it gets activated, switches on genes that increase cholesterol production and LDL receptor expression, and restores the balance. When cholesterol is abundant, Insig binds to Scap and keeps the whole complex locked in place, preventing those genes from switching on.16PubMed. Structural basis for sterol sensing by Scap and Insig This feedback loop is the reason statins work: by blocking the cell’s own cholesterol production, statins trick the cell into making more LDL receptors, pulling more LDL out of the bloodstream.
When Lipoproteins Drive Atherosclerosis
The connection between lipoproteins and heart disease centers on what happens when LDL particles linger in the bloodstream too long and penetrate the walls of arteries. Once trapped in the artery wall, LDL undergoes chemical modifications, most critically oxidation, which changes its surface in ways that attract immune cells. Oxidized LDL is a key trigger for the cascade of inflammation that defines atherosclerosis.17PubMed Central. Mechanisms of Oxidized LDL-Mediated Endothelial Dysfunction and Its Consequences for the Development of Atherosclerosis
Macrophages, a type of immune cell, rush in to swallow the oxidized LDL. But unlike normal LDL uptake through the regulated LDL receptor, macrophages gobble up oxidized LDL through scavenger receptors that have no off switch. The macrophages become bloated with cholesterol, turning into what pathologists call foam cells, the hallmark of early atherosclerotic plaques.18PubMed Central. VPO1 mediates oxidation of LDL and formation of foam cells Over time, these plaques grow, harden, and can eventually rupture, triggering clots that cause heart attacks or strokes.
Remnant lipoproteins, the partially processed leftovers of chylomicrons and VLDL, also contribute to this process. Because remnants are small enough to enter artery walls yet still carry substantial cholesterol, they are considered highly atherogenic. Growing evidence suggests that remnant lipoproteins play a central role in the cardiovascular risk that persists even in people whose LDL cholesterol is well controlled.19PubMed. Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease
Lipoprotein(a): The Inherited Wildcard
Lipoprotein(a), usually written Lp(a), is an LDL-like particle with an extra protein attached: apolipoprotein(a), which is bound to apoB-100 through a single disulfide bridge.20PubMed Central. Lipoprotein (a): structure, pathophysiology and clinical implications What makes Lp(a) unusual is that apolipoprotein(a) looks structurally similar to plasminogen, a protein involved in dissolving blood clots. This resemblance may allow Lp(a) to interfere with the clotting system while simultaneously depositing cholesterol in artery walls, giving it a double-edged atherogenic punch.21European Cardiology Review. Presumed Mechanisms Underlying Lipoprotein(a)-caused Atherosclerosis
Lp(a) levels are largely determined by genetics and are resistant to the lifestyle changes and standard medications that lower LDL. This is why Lp(a) has become a major target for next-generation therapies. RNA-silencing approaches, including antisense oligonucleotides and small interfering RNA, are now in clinical trials aimed at cutting the liver’s production of apolipoprotein(a) and thereby reducing Lp(a) levels in people at high cardiovascular risk.22PubMed. The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
Lipoproteins in the Brain
The brain is the most cholesterol-rich organ in the body, yet it operates its own largely independent lipid transport system. The blood-brain barrier blocks most circulating lipoproteins from entering, so brain cells manufacture their own cholesterol and move it around on HDL-like particles.23Exploration of Neuroprotective Therapy. Balancing cholesterol in the brain: from synthesis to disposal Astrocytes are the primary cholesterol exporters, loading the sterol onto particles carrying apoE and apoJ (also known as clusterin). Neurons, which have high cholesterol demands for synapse maintenance and signaling, take up these particles to meet their needs.
ApoE is the dominant lipoprotein in the central nervous system and is produced mainly by astrocytes, though neurons themselves can start making it under stressful conditions.24PubMed Central. Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism The gene encoding apoE comes in three common variants (E2, E3, E4), and the E4 variant is the strongest common genetic risk factor for Alzheimer’s disease. While the exact mechanism is still debated, impaired cholesterol recycling in the brain is thought to contribute to neurodegeneration. This means the lipoprotein story extends well beyond the cardiovascular system.
HDL and the Immune System
HDL does more than move cholesterol around. It also participates in innate immunity by neutralizing bacterial toxins. When gram-negative bacteria release endotoxin (lipopolysaccharide, or LPS) into the bloodstream, HDL can bind and sequester it. One HDL-associated protein, apoM, binds endotoxin with high affinity and helps prevent it from triggering an exaggerated inflammatory response. In lab experiments, purified HDL significantly reduced the release of the inflammatory signal TNF-alpha from human immune cells exposed to bacterial endotoxin.25Biochemistry and Biophysics Reports. ApoM binds endotoxin contributing to neutralization and clearance by High Density Lipoprotein This immune function may partly explain why very low HDL levels are associated with worse outcomes during severe infections, separate from any cardiovascular effects.
Lipoproteins Follow a Circadian Clock
Your lipoprotein levels are not static throughout the day. Triglycerides, in particular, show pronounced circadian rhythms, with the liver and intestine producing lipoproteins on a schedule set partly by internal clock genes. Research has found that many of the proteins involved in intestinal fat absorption and lipoprotein assembly follow rhythmic patterns of expression, driven by the same molecular clock machinery that governs sleep-wake cycles.26Journal of Lipid Research. Circadian regulation of lipid metabolism This has practical implications: the timing of meals can influence postprandial lipid spikes, and some researchers believe that circadian misalignment (from shift work, chronic jet lag, or irregular eating patterns) may contribute to the elevated cardiovascular risk seen in those populations.
Advanced Lipoprotein Testing
Standard blood lipid panels report total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. These measurements tell you how much cholesterol is carried in each fraction, but not how many particles are doing the carrying or how large those particles are. Nuclear magnetic resonance (NMR) spectroscopy can measure particle number and size directly.27PubMed Central. Clinical Relevance of Nuclear Magnetic Resonance LipoProfile This matters because two people with identical LDL cholesterol levels can have very different numbers of LDL particles. A person with many small, dense LDL particles may carry more atherogenic risk than someone with fewer large particles, even if the total cholesterol carried is the same. NMR-based testing is increasingly used when standard panels leave an unclear risk picture, such as in people with normal LDL cholesterol but elevated triglycerides.
An Ancient Transport System
The lipoprotein system did not appear out of nowhere in mammals. ApoB-100, the defining protein of LDL and VLDL, shares structural domains with vitellogenin, an ancient protein that shuttles lipids into egg yolks in everything from insects to fish. Sequence analysis has shown that vitellogenins from organisms as distantly related as roundworms and fruit flies contain regions homologous to human apoB-100 and lipoprotein lipase. The interpretation is that a precursor gene originally used for packaging lipids into eggs was duplicated and repurposed over evolutionary time to serve the very different job of circulating lipids through the blood of vertebrates.28Biochemical Journal. Is vitellogenin an ancestor of apolipoprotein B-100 of human low-density lipoprotein and human lipoprotein lipase? It is a reminder that evolution tends to modify existing tools rather than invent new ones, and the lipid transport problem is far older than the circulatory systems that now depend on lipoproteins to solve it.